Get started

Investment

Rumours Swirl About Agape ATP’s Big Move – Is ATP2 Making a ComeWord on the street is that Agape ATP Corporation (NASDAQ: ATPC) might be gearing up for a major play. According to hearsay from one of the investors, Agape Superior Living, a subsidiary of ATPC, could be bringing back its flagship product, ATP2, as soon as mid to late this month. If the whispers are true, this could mean big things for the company. For those who’ve been following, the ATP Zeta Health Program which includes eight health and wellness products, there is a solid track record. The program hit a massive RM18 million in monthly sales in March 2018 and totalled RM62 million for the year. ATP2, in particular, has always been the star of the show, loved for its health benefits with strong customer loyalty. Should this relaunch happen, it could reignite serious consumer interest. After all, wellness products are in huge demand right now. Agape Superior Living might just be timing this perfectly to ride the wave of the health trend. If they pull this off, we could see some big numbers in terms of sales, which would be a win for the company and its investors. For those watching ATPC’s stock, this could be a golden opportunity. The company’s products have a history of doing well, and if ATP2’s relaunch sparks the same kind of sales it did before the pandemic, it could signal a new growth phase for Agape Superior Living. Investors are keeping a close eye on this, and some are saying this could be the beginning of something big. So, while nothing official has been confirmed just yet, if you’re an investor in ATPC or thinking about jumping in, you might want to watch what happens over the next few weeks. ATP2’s potential comeback could be the catalyst for renewed growth and profitability in the health and wellness space. Stay tuned. If the rumours are true, we could be looking at some exciting times ahead for Agape ATP Corporation. NASDAQ:ATPC
NASDAQ:ATPCLong
by HASHInvests200
ROSSARI BIOTECH Showing Change in Price StructureNSE:ROSSARI .................................................................................................................... .................................................................................................................... .................................................................................................................... Update on the expansion projects at Dahej Facilities .................................................................................................................... • In the Q2FY24 the Company had announced an expansion of its facility at Dahej by adding up 20,000 MTPA capacity for products related to HPPC in the specialty chemical space, as well as for producing ingredients for its subsidiary companies. Also, to cater to the growing demand in agro chemicals, home and personal care, oil & gas and the pharma sector, the Company had further announced expansion of the Ethoxylation capacity by 30,000 MTPA at the Dahej facility of Unitop Chemicals Private Limited. • Work on both these projects are progressing as planned. Commissioning is expected to happen, in a phased manner in the current year .................................................................................................................... .................................................................................................................... .................................................................................................................... • Consistent growth trajectory over the past three years, driven by both organic and inorganic growth strategies • While near-term investments and strategic initiatives have led to a moderation in ROCE and ROE, the balance sheet position remains strong. The Company is confident of reporting improved return metrics in the future as these investments start yielding results
NSE:ROSSARILong
by iism-ExpertTrading
NOC vs LMT: A Valuation War Between Top Defence Manufacturers!ABOUT COMPANIES Northrop Grumman NYSE:NOC excels in advanced aircraft systems, divided into four main areas: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. Aeronautics Systems designs and manufactures cutting-edge aircraft for the U.S. military and global clients. Defense Systems integrates battle management and weaponry, while Mission Systems delivers innovative solutions for defense and intelligence. Space Systems focuses on solutions for national security and commercial purposes. Established in 1939 by John K. Northrop and others, the company is headquartered in Falls Church, VA. Lockheed Martin NYSE:LMT stands as a top global security and aerospace company, dedicated to the research, design, and production of advanced technology systems. It operates in four primary segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment focuses on military aircraft, including combat and drones. MFC specializes in air and missile defense and precision strike systems. RMS develops military and commercial helicopters and cyber solutions, while the Space segment creates satellites and defense systems. Founded in 1912, the company is located in Bethesda, MD. MARKET CAPITALIZATION ● Northrop Grumman (NYSE: NOC) - $75.96 Billion ● Lockheed Martin (NYSE: LMT) - $135.53 Billion TECHNICAL ASPECTS ● Northrop Grumman ➖ The monthly chart shows that the stock price is currently on a distinct upward path. ➖ Previously, it faced resistance around the $360 level, caused a notable pullback. ➖ Subsequently, the price formed a Double Bottom pattern and broke out successfully. ➖ This breakout drove the price to an all-time high near the $556 level but the price started declining from there. ➖ Nevertheless, the stock price found strong support around the $420 level, allowed it to bounce back. ➖ Currently, the stock is approaching its previous all-time high, and if it can overcome that resistance, we can anticipate further price increases in the coming days. ● Lockheed Martin ➖ This stock is on a strong upward trajectory, consistently achieving higher highs and higher lows. ➖ Following a significant breakout around the $500 mark, the stock price surged and is now trading at $568.5, just shy of its all-time peak of $578.7. ➖ From a technical perspective, the price is hovering just below the upper boundary of a parallel channel, which may act as a resistance point. ➖ However, if the price can break through this range and maintain that momentum, we could see even greater upward movement ahead. Relative Strength ● The chart shows that the NYSE Composite TVC:NYA has provided a solid return on investment of about 18% in the last year. In comparison, Northrop Grumman and Lockheed Martin have done even better, with returns of around 20% and 27%, respectively. REVENUE BREAKDOWN ● Northrop Grumman The company derives its income from four main segments. ➖ The largest share comes from the space systems segment, contributing around 33%, which equates to $14.34 billion out of a total revenue of $43 billion. ➖ Next, the aeronautics systems segment adds nearly 27%, bringing in $11.61 billion of the overall revenue. ➖ The mission systems segment follows closely, accounting for about 26%, or $11.12 billion of the total. ➖ Finally, the defense systems segment generates nearly 14%, totaling $5.99 billion of the overall revenue. ● Lockheed Martin Similar to Northrop Grumman, this company also operates through four segments to drive its revenue. ➖ The aeronautics segment leads the way, contributing around 38.4%, which amounts to nearly $28.77 billion of the total revenue of $74.85 billion. ➖ The rotary and mission systems segment accounts for 26.4% of revenue, equating to $19.76 billion. ➖ Next, the space segment contributes 17.8%, which is $13.33 billion. ➖ Finally, the missile and fire control segment makes up 17.4%, totaling $12.99 billion of the overall revenue. REVENUE & PROFIT ANALYSIS ● Northrop Grumman Revenue ➖ For the FY23 the revenue has jumped by 7.3% to $39.3 B from $36.6 B in FY22. ➖ In the recent June quarter there is no significant surge in revenue as the recent quarterly revenue stands at $10.2 B compared to $10.1 B in the march 2024. But from the last year June quarter the revenue has grown by almost 6% from $9.6 B. Profit ➖ The operating profit has experienced a decline, with FY23 reporting only $2.9 billion, a drop from $6.3 billion in FY22. ➖ In the latest June quarter, the operating profit held steady at $1.3 billion, unchanged from the March quarter. Basic EPS (LTM) ➖ The basic EPS saw a slight rise in June, climbing to $15.26 (LTM) from $14.33 (LTM) in March 2024. However, compared to the same quarter last year, there has been a significant drop from $30.23 (LTM) Analyzing these numbers shows that although revenue has risen, the company is having difficulty producing profits, which may impact the share price in the near term. ● Lockheed Martin Revenue ➖ In FY23, the company experienced a slight revenue increase of 2.4%, rising to $67.6 billion from $66 billion in FY22. ➖ During the recent June quarter, revenue reached $18.1 billion, up from $17.2 billion in the March quarter. Compared to the same quarter last year, this represents a significant growth of approximately 8.6%, up from $16.7 billion. Profit ➖ The operating income has experienced a year-over-year increase. For FY23, it reached $9.0 billion, marking a 23% rise from $7.3 billion in FY22. ➖ However, there hasn't been a notable change in operating profit on a quarter-over-quarter basis. In June, the operating profit stood at $2.2 billion, slightly up from $2.1 billion in March. This figure is consistent with the operating profit reported in the same quarter last year. Basic EPS (LTM) ➖ The basic EPS stood at $27.58 (LTM) in June 2024 ➖ Over the past year, there has been no notable growth in EPS (LTM) Lockheed Martin demonstrates a more robust financial standing compared to Northman Grumman. VALUATION ● P/E Ratio ➖ P/E vs. Median P/E (1) Northrop Grumman's current price-to-earnings ratio over the past twelve months stands at 33.2x, which appears elevated when compared to its four-year median of 15.2x. (2) Lockheed Martin's recent twelve-month p/e ratio is 20.1x, also showing a rise relative to its four-year median of 16.2x. ➖ P/E vs. Industry P/E (1) NOC shows a fair valuation with a Price-To-Earnings Ratio of 33.2x, which is just below the US Aerospace & Defense Industry average of 33.3x. (2) On the other hand, LMT, with a P/E of 20.1x, seems to be undervalued relative to the industry average of 33.3x. ● P/B Ratio ➖ NOC's current P/B ratio of 5.3x appears inflated when stacked against the US Aerospace & Defense Industry average of 3.2x. ➖ In the case of LMT, it stands out as significantly overvalued, boasting a P/B ratio of 21.9x, which is far above the industry average of 3.2x. FREE CASH FLOW ANALYSIS ● Northrop Grumman ➖ In FY23, cash flow from operations saw a remarkable increase, climbing to $3.9 billion, a notable rise from $2.9 billion in FY22. ➖ In the most recent quarter, this figure reached $4.4 billion, up from $3.9 billion in March. ● Lockheed Martin ➖ There was little change in operating cash flow, with FY23 reporting $7.9 billion, which is nearly the same as the $7.8 billion recorded in FY22. ➖ On a quarterly basis, there has been an uptick; for the June quarter, operating cash flow stood at $8.8 billion, an increase from $8.0 billion in March and $7.7 billion in the same quarter last year. DEBT ANALYSIS ● NOC currently has a debt of $16.3 billion, resulting in a debt-to-equity ratio of 114%. While this may raise some concerns, the company boasts an interest coverage ratio of 5.2, indicating a solid ability to manage interest payments on its debt. ● In contrast, LMT carries a debt of $19.3 billion, leading to a debt-to-equity ratio of 311%, which suggests poor financial health. However, with an impressive interest coverage ratio of 8.9, the company is in a strong position to meet its interest obligations. TOP SHAREHOLDERS ● Northrop Grumman ➖ State Street Global has a notable 9.59% ownership in this firm, while The Vanguard Group possesses a considerable 8.22% stake. ● Lockheed Martin ➖ In addition to the 11.2% held by Lockheed Martin's Employee Stock Ownership Plan (ESOP), State Street Global and The Vanguard Group own 15.1% and 8.99% respectively. ➖ BlackRock also maintains a significant 7.13% interest in this company. CONCLUSION After reviewing all the financial metrics, it becomes evident that each company possesses distinct strengths and weaknesses. It's difficult to determine which one is the superior investment choice at this moment. A look at the monthly chart indicates that both companies are currently at a high point, but they could be good candidates for accumulation during any significant downturns. In 2023, the US spent $916 billion on defense, which was more than any other country. This was an increase of $55 billion from 2022. and this figure could increase given the current global landscape. Therefore, companies like Northrop Grumman and Lockheed Martin are expected to perform well in the foreseeable future.
NYSE:NOCLong
by NaranjCapital
Raj Rayon : {"Potential for Best investment for 2024";} We are at the Biggest Picture available as per the data; Price has formed a Wave 1 which is an Impulse Wave In the Upward direction; Wave 2 is a downward 3-Wave-Simple-Correction Structure, retracing Wave 1 by less than a 100% which suffices the Laws of Wave as per the Elliott Wave Theory and now. ====================================================================== Let's talk about the most interesting part The Most Awaited Wave 3 is expected to come out, showing the move which is the reason why we trade, According to the Elliot Wave Theory the Projection of Wave 3 is at least 161.80% of the Wave 1. Let's see on the charts the Extension Levels as per the Best Leading Indicactor Fibonacci Extension; Yo !!!! Now Last Month that's in August 24, Price has closed above the EMA and hence I see a Buying Momentum in the Monthly chart, Looking at the Promotor Holding of this company which is more than 90% only confirms my belief in the future growth of the company. So we have an Overall Target Projection of Rs. 158.03 {Derived as per Fibonacci Extension} Now Let's look at the other side the {downside/ stop loss/ risk against the reward}
NSE:RAJRILTDLong
by WavesandZones
Can 128% be soon?Cardano (ADA) is one of my favourite coins which I choose to invest in. This is trade (investment) setup on larger timeframe. If you never bought ADA before it is still not late. I am not looking to reach targets 2,3,4 very soon, that could be year(s). I will sell most of my capital on targets 2,3. Small portion will be sold on Target 1 and hopefully on Target 4. Entry Zone: 0.50 – 0.57 Buy Zone 1: 0.30 – 0.37 Buy Zone 2: 0.13 – 0.16 Target 1: 1.33 – 1.44 (128%) Target 2: 2.83 – 2.93 (390%) Target 3: 4.35 – 4.89 (651%) Target 4: 5.73 – 5.84 (891%)
Long
by Abmoon
6
Concerned about aging? Start investing in Addus now!The aging U.S. population is set to double by 2050, increasing the need for caregivers. Addus HomeCare Corporation, based in Frisco, Texas, provides essential personal care, hospice, and home health services. With a market cap of $2.35 billion, Addus reported $1.115 billion in revenue in June 2024, with a 27% profit increase. The company is debt-free and has major shareholders like Blackrock and The Vanguard Group. EPS is forecasted to grow significantly by December 2025. With a growing need for home healthcare services, the company is well-positioned to expand its customer base and market presence. Company Overview Addus HomeCare Corporation and its subsidiaries offer personal care services for the elderly, disabled, and those at risk of hospitalization in the U.S. It operates in three areas: Personal Care, Hospice, and Home Health. The Personal Care segment helps with daily activities like bathing, grooming, and meal preparation. The Hospice segment provides care and support for terminally ill patients and their families. The Home Health segment delivers skilled nursing and therapy services for those recovering from illness or hospitalization. Its clients include government agencies, managed care organizations, insurers, and private individuals. Founded in 1979, Addus is based in Frisco, Texas. Investment Advice by Naranj Capital Buy Addus Homecare Corporation NASDAQ:ADUS ● Buy Range- 120 - 125 ● Target- 150 - 160 ● Potential Return- 25-30% ● Duration- 10 -12 Months Market Capitalization - $ 2.35B Sector - Healthcare (Nursing) Technical Analysis ● The monthly chart indicates a clear upward trend in prices. ● Earlier, the stock peaked near the 129 (128.8 to be precise) level before experiencing a correction, which was subsequently followed by an elongated consolidation period from November 2020 to July 2024. ● Recently, the stock has successfully made a multi-year breakout of the previous resistance zone and has maintained its position above this breakout level. ● We expect this momentum to persist, leading to further price increases in the days ahead. Entry, Exit & Stop-loss ● Entry with Capital allocation strategy (1) consider adding 50% of your desired quantity at the current market price (132 - 133). (2) The second buying opportunity will be in the 120 - 122 range, where you can also add rest 50% of your quantity. ● Target Chart analysis indicates a promising upside potential of 25-30% for this stock from the best buying level, with a target around the 155 to 160. There is also a strong likelihood that the stock could exceed this target. ● Stoploss It is crucial to implement a strict stop-loss below the 115 level, as we anticipate that the stock may encounter challenges if it drops to this point. Revenue Breakdown The company generates its revenue through three primary segments. (1) The personal care sector represents around 74.2% of the overall revenue, totaling $827 million out of $1.11 billion. (2) Meanwhile, hospice services contribute nearly 19.7%, amounting to $219.8 million of the total revenue. (3) The home health segment accounts for approximately 6.1%, which translates to $67.8 million of the overall revenue. Sales & Profit Analysis ● A noticeable rise in revenue has been observed. For the June quarter, revenue reached $1.115 billion, marking an 11.6% increase from $999 million in June 2023 (YoY) and a 2.5% rise from $1.08 billion in March 2024 (QoQ). ● Additionally, profits surged by 27% in the latest quarter, climbing to $68.89 million from $53.83 million in the same quarter last year, and up 5% from $65.67 million in March 2024. ● The profit margin has also improved, increasing from 5.4% to 6.2% year-on-year. ● The basic EPS for the June 2024 quarter is reported at 4.28, marking a significant increase of 27% from 3.37 in the same quarter last year. Peer Companies (1) Privia Health Group (NASDAQ: PRVA) - $ 2.41B NASDAQ:PRVA (2) Amedisys (NASDAQ: AMED) - $ 3.21B NASDAQ:AMED (3) Astrana Health (NASDAQ: ASTH) - $ 2.33B NASDAQ:ASTH Valuation ● P/E vs Fair P/E Ratio ➖ The current PE ratio stands at 34.1x, slightly expensive to the estimated Fair PE of 28.7x. ● P/E Ratio vs Peers ➖ ADUS offers great value with a Price-To-Earnings Ratio of 34.1x, significantly lower than the peer average of 62.7x. ● P/E Ratio vs Industry P/E ➖ ADUS seems to come at a higher price, boasting a Price-To-Earnings Ratio of 34.1x, notably surpassing the US Healthcare industry average of 26.2x. Debt Analysis ➖ ADUS stands proudly as a debt-free entity, a remarkable transformation from five years ago when its debt to equity ratio stood at 12.9%. This significant shift underscores the company's commitment to financial health and stability. Top Shareholders ● Blackrock currently holds a substantial 16% stake in this stock, reflecting an impressive increase of 11.2% since the March quarter. ● Meanwhile, The Vanguard Group has also boosted its investment, raising its stake by 8.5% from the previous quarter, bringing their total holding to 7.74%. Earnings per Share Growth Forecasts Experts forecast that the earnings per share (EPS) could increase from $4.28 to $4.51 by December 2024, and further rise to $5.03 by December 2025. Conclusion With the growing need for home healthcare services, the company is well-positioned to broaden its customer base and enhance its market presence.
NASDAQ:ADUSLong
by NaranjCapital
1
NASDAQ: ATPC Spiked 65% Pre-Market Upon Successful Reverse Stock Agape ATP Corporation (ATPC) saw an impressive 65% spike in pre-market trading today, a clear indication of investor confidence following the company’s recent 20:1 reverse stock split. This strategic move appears to have paid off, significantly boosting the stock price and attracting renewed interest from both institutional and retail investors. The reverse stock split, which consolidated shares to enhance market stability and meet Nasdaq listing requirements, has evidently strengthened ATPC’s market position, setting the stage for further growth in the renewable energy sector. Investors are now eyeing ATPC as a promising player in the green energy landscape, with the recent price surge reflecting growing optimism about the company's future prospects. As the renewable energy sector continues to gain momentum, ATPC's strategic decisions, including this reverse split, are likely to play a crucial role in its long-term success.
NASDAQ:ATPCLong
by HASHInvests200
Good time to buy and HODL!Arweave (AR) is one of my recent coins which I choose to invest in. This is trade (investment) setup on larger timeframe. I am not looking to reach targets 2,3,4 and 5 very soon, that could be year(s). I will sell most of my capital on targets 2,3. Small portion will be sold on Target 1 and on Target 4 and 5. Entry Zone: 9.07 – 11.07 Buy Zone 1: 6.06 – 7.36 Target 1: 26.03 – 28.75 (135%) Target 2: 38.39 – 42.25 (247%) Target 3: 56.98 – 60.36 (432%) Target 4: 75.92 – 78.98 (609%) Target 5: 93.40 – 99.77 (774%)
Long
by Abmoon
16
Apple (AAPL): Swing Entry on the HorizonLast time, we narrowly missed the entry on Apple by just a few dollars, and after that miss, the stock no longer presented a compelling opportunity, so we decided to wait. However, after observing from the sidelines for a few months, it seems that another chance to secure a profitable swing entry might be approaching. To increase our confidence in this potential opportunity and secure a better entry point, we need to closely monitor further movements from this tech giant. The current price action strongly suggests that a flat pattern might be forming following the recent drop. If this flat pattern does materialize, it could manifest as either a regular flat or an expanded flat, and this will be crucial in determining our entry target zone. At this stage, the area between $200 and $180 seems the most probable and attractive for a potential entry. Given the broader market trends and Apple’s recent performance, this zone could offer a favorable risk-reward ratio. We’ll be watching for any developments that confirm this pattern and provide a clearer signal for entry. Stay tuned for further updates as we refine our strategy and prepare for a possible move on Apple.
NASDAQ:AAPLLong
by freeguy_by_wmc
S&P 500 Daily Chart Analysis For Week of Aug 23, 2024Technical Analysis and Outlook: Throughout the current week's trading session, the S&P 500 Index has demonstrated notable resilience, surpassing the Mean Resistance level of 5564 and positioning itself beneath the attained Inner Index Rally at 5666. The prevailing price action indicates a sustained upward momentum aimed at retesting the completed Interim Index Rally at 5666, with an eye on the subsequent upside objectives represented by the Inner Index Rally at 5745 and the ultimate Outer Index Rally at 5840. It is important to note that the attainment of these targets is likely to prompt a selling price action.
SP:SPX
by TradeSelecter
Sanofi (SNY): A Strong Investment CaseCompany Overview: Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion. Investment Highlights: Dividend Yield: 3.8%, more than double the S&P 500 average. Drug Portfolio: Diverse and includes successful drug developments. Pipeline: Promising future drug pipeline with potential for growth. Berkshire Hathaway Investment: Long-standing investment from Berkshire Hathaway underscores the company’s attractiveness and stability. Outlook: We are bullish on SNY due to its growth potential and solid dividend payout. The combination of a strong drug portfolio, promising pipeline, and robust dividend makes Sanofi a compelling investment choice. #Sanofi #SNY #Pharmaceuticals #Investment #DividendYield #MarketCap #GrowthPotential #BerkshireHathaway #StockAnalysis #Bullish
NASDAQ:SNYLong
by Richtv_official
Chevron (CVX): Approaching a Critical Support ZoneIt's been a while since we last analyzed CVX, but we’re now approaching a very important area on the chart. You might wonder why we’re focusing on the weekly chart instead of the daily. The reason is simple: sometimes you need to zoom out to get a clearer perspective, and in this case, the weekly chart holds far more significance than the daily. There’s no point in searching for entries on the daily when the more crucial entry level on the weekly is just below. We’re looking to find support at the HVN POC (High Volume Node Point of Control) at $117, which would also serve as a retest after the last breakout in 2022. We’re still determining the best way to place a limit order at this level, but for now, we’re waiting on the sidelines with alerts set and a light game plan ready.
NYSE:CVXLong
by freeguy_by_wmc